Twitxy Saved

Michael Foley

@MikeFoley89

Cardiology Registrar | MRC Clinical Research Training Fellow | Imperial College London
London, England Joined September 2010
331 Following 268 Followers 51 Posts

Latest posts 5

Michael Foley @MikeFoley89
I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. @rallamee
Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective tctmd.com/news/mechanism…
View quoted post on X
1 replies 5 reposts 17 likes 4.8K views View on X
Michael Foley @MikeFoley89
Delighted to see our ORBITA-COSMIC design paper published in Eurointervention. Now for the results! My thanks as ever to my supervisors and the incredible ORBITA team @rallamee @mshunshin @rajkumar_chris @fiyyazAJ @FloSimader @drgrahamcole @ProfDFrancis
Davide Capodanno Verified account @DFCapodanno Jan 10, 2024
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. eurointervention.pcronline.com/article/a-doub…
View quoted post on X
0 replies 4 reposts 31 likes 3.4K views View on X